Welcome to CorSolutions where we give you the benefit of our consulting expertise and what we see happening in the industry. We hope this blog helps our clients and potential business colleagues answer some of their pressing cardiovascular discovery and safety pharmacology questions. Please feel free to comment; we welcome your insight as well.
Pulmonary hypertension (PH) is a rare disorder arising from elevated pulmonary blood pressure, usually due to constriction of the pulmonary vasculature.
At CorDynamics, we address pulmonary hypertension as a complex disorder involving consideration of several physiological systems for its study, diagnosis and treatment. Though no single animal model of PH fully mimics its clinical course, together, [...]
My team and I are returning from the 2009 Safety Pharmacology Society meeting in Strasbourg, France. With us was our lead veterinary technician, Ms. Melissa Fisher, who was awarded a Junior Investigator Travel Award for her work with her colleagues developing a model of hypoxic pulmonary vasoconstriction / pulmonary arterial hypertension (PAH) in the cynomolgus [...]
© 2009 CorDynamics - Site by RJ Conlin